Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Caisson Laboratories
AddedFeb 16, 2024
UpdatedJun 18, 2026
Caisson Laboratories

Caisson Laboratories

US-based Caisson Laboratories Inc, founded in 1998, specializes in commercial bio-physical research.

HQ
Smithfield, UT, US
Founded
2000
Overview
Compare
Fundraising
Employees
Website

Caisson Laboratories Inc, founded in 1998 and based in North Logan, United States, specializes in commercial bio-physical research. The company's core mission is to advance scientific research by providing high-quality reagents and supplies for animal cell and plant tissue culture. Their product offerings include fetal bovine serum, IMDM, DMEM, sodium phosphate, antibiotics, biochemicals, gelling agents, and various molecular biology and microbiology tools. Caisson Labs focuses on supporting researchers in both academic and industrial markets.

Notable affiliated individuals and investors have not been publicly disclosed. Key achievements include establishing a robust catalog of essential reagents and supplies that are widely used in scientific research laboratories. Caisson Laboratories has made a significant impact by ensuring the availability of critical materials necessary for advancements in biological and physical sciences, contributing to the progress of research in fields such as molecular biology, microbiology, and plant biology.

Caisson Laboratories - Quick Facts

When was Caisson Laboratories founded?

Caisson Laboratories was founded in 2000.

Where is Caisson Laboratories' headquarters located?

Caisson Laboratories' headquarters is located in Smithfield, UT, US.

When was Caisson Laboratories' last funding round?

Caisson Laboratories' most recent funding round was for $50k (USD) in December 2010.

How much has Caisson Laboratories raised to-date?

As of Dec 20, 2010, Caisson Laboratories has raised a total of $50k (USD).

How many employees does Caisson Laboratories have?

Caisson Laboratories has 30 employees as of Feb 5, 2024.

Caisson Laboratories - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Transactional
Customer
  • Education
  • Enterprise
Main Product
  • Reagents
  • Supplies
Tags
  • Distribution
  • eCommerce
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
ISIC
  • 7320Market research and public opinion polling
Show 15 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 541910Marketing Research and Public Opinion Polling
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 541900Other Professional, Scientific, and Technical Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 8732Commercial Economic, Sociological, And Educational Research
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified